RCM
ZYNE

RA Capital Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

RA Capital Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-253,468
Closed -$1.74M – 34
2016
Q2 		$1.74M Sell
253,468
-253,723
-50% -$2.12M 0.24% 30
2016
Q1 		$4.79M Hold
507,191
– – 0.61% 33
2015
Q4 		$5.11M Sell
507,191
-17,809
-3% -$236K 0.51% 30
2015
Q3 		$7.51M Buy
+525,000
New +$12.9M 1.08% 30

Other funds holding ZYNE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
AAM
Auxier Asset Management Aurora, Oregon $696M AUM 18.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RA Capital Management's ZYNE Position: Q3 2016 in Review

RA Capital Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2016, closing a stake of 253,468 shares — an estimated $1.74M sold.

RA Capital Management first reported a position in ZYNE in Q3 2015 and held it in 4 quarters. The position peaked at $7.51M in Q3 2015. 21 funds tracked by Wall St. Rank hold ZYNE as of Q3 2016.

  • RA Capital Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2016 after selling out during the quarter.
  • RA Capital Management sold 253,468 Zynerba Pharmaceuticals, Inc shares in Q3 2016, an estimated $1.74M.
  • RA Capital Management first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2015 and held it in 4 quarters.
  • RA Capital Management's Zynerba Pharmaceuticals, Inc position peaked at $7.51M in Q3 2015.
  • 21 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2016.

Based on RA Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.